Upcoming event

Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time

BJU International, March 2023

Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma

European Urology Oncology, October 2023

Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases – An analysis of European multi-centre prospective EuRECA registry

Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?

Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: results from a prospective observational study

Development of an individual postoperative prediction model for kidney cancer recurrence using machine learning (UroCCR study 120)

Quality of life outcomes after robotic-assisted versus open partial nephrectomy: Results from the randomized ROBOCOP II trial

89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study

Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups

European Urology Open Science, January 2023

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)

STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)